FDA Inspects Helix3 With No Findings
The U.S. Food & Drug Administration Bioresearch Monitoring Program reports no findings following an onsite inspection of Helix3 in April 2022. These results clearly demonstrate Helix3's commitment to quality and the effectiveness of our program.
Commentaires